Company

Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area.

Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development and commercialization. Our goal is to leverage our myeloid biology expertise to discover, develop and commercialize transformative treatments to address key unmet medical needs for patients with cancer.

Management Team

Randall Schatzman, Ph.D.

Chief Executive Officer

Randall Schatzman, Ph.D., Chief Executive Officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. P

Randall Schatzman, Ph.D.

Chief Executive Officer

Randall Schatzman, Ph.D., Chief Executive Officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president, chief executive officer, co-founder and board member of Alder, from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: Vyepti (eptinezumab), approved for the preventive treatment of migraine in adults, and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder BioPharmaceuticals, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered Evenity (romosozumab), which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience, where he served as preclinical team leader for Cytovene (ganciclovir) and team leader for Valcyte (valganciclovir hydrochloride), both of which are currently marketed drugs.

Dr. Schatzman received his Ph.D. in molecular pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer-reviewed scientific publications.

Edith A. Perez, M.D.

Chief Medical Officer

Edith A. Perez, M.D., Chief Medical Officer, is an internationally recognized translational researcher and cancer specialist known for her strategic visi

Edith A. Perez, M.D.

Chief Medical Officer

Edith A. Perez, M.D., Chief Medical Officer, is an internationally recognized translational researcher and cancer specialist known for her strategic vision in innovative and patient-centric clinical trial design. Dr. Perez joined Bolt in 2020 and has set direction for the organization’s clinical strategy and development and oversees regulatory affairs, pharmacovigilance, biostatistics, and medical affairs for the company’s diverse clinical development and early-stage immuno-oncology pipeline.

In addition to her work at Bolt Biotherapeutics, Dr. Perez is professor of medicine at Mayo Clinic, where she has practiced for over two decades. She is chair of the Health Equity Committee and a member of the Scientific Advisory Committee for Stand Up to Cancer, a member of the Puerto Rico Science, Technology & Research Trust and has been involved in diversity leadership and philanthropic initiatives with the American Society of Clinical Oncology, the American Association for Cancer Research and The DONNA Foundation. Dr. Perez also serves on the editorial boards of multiple academic journals and is a member of the Board of Directors and the Clinical Advisory Board for Artiva Biotherapeutics. Prior to joining Bolt, Dr. Perez was vice president and head of the BioOncology-U.S. Medical Affairs unit at Genentech, a member of the Roche Group, where she oversaw all U.S. hematology and oncology medical affairs. In that role, Dr. Perez led hundreds of trials and was involved in the launch of six drugs, including Gazyva (obinutuzumab) for patients with lymphoma, Perjeta (pertuzumab) for patients with early-stage HER2+ breast cancer, Alesensa (alectinib) for patients with lung cancer and Tecentriq (atezolizumab) for bladder cancer and non-small cell lung cancer patients.

Dr. Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. In addition, Dr. Perez completed her fellowship training at the University of California, Davis. She also completed the Executive Development Program at the Harvard Kennedy School and the Executive Leadership and the Management Executive Programs at the Wharton School of the University of Pennsylvania. Dr. Perez is board certified in internal medicine, medical oncology, and hematology.

William Quinn

Chief Financial Officer

Willie Quinn, Chief Financial Officer, joined Bolt Biotherapeutics in 2020, bringing extensive experience in finance, operations, and business developmen

William Quinn

Chief Financial Officer

Willie Quinn, Chief Financial Officer, joined Bolt Biotherapeutics in 2020, bringing extensive experience in finance, operations, and business development leadership in the biopharma industry. Prior to joining Bolt, Mr. Quinn served as the chief financial officer and senior vice president of corporate development at Sunesis Pharmaceuticals (acquired by Viracta Therapeutics), where he led the company through multiple public financings and corporate collaborations. Before joining Sunesis, Mr. Quinn co-founded and was chief executive officer of Bullet Biotechnology, an immuno-oncology company developing therapeutic cancer vaccines discovered at Stanford University. Previously, Mr. Quinn was instrumental in establishing the infrastructure at Jazz Pharmaceuticals, where he was one of the first employees. During his eight years at Jazz, Mr. Quinn held positions of increasing responsibility in operations and business development as the company transformed from a privately held startup to a public and profitable specialty pharmaceutical company identifying, developing, and commercializing pharmaceutical products in neurology and psychiatry. Mr. Quinn’s final role with Jazz was leading corporate development, including product licensing, M&A, strategy, and investor relations. Prior to joining Jazz, Mr. Quinn was the chief financial officer and chief operating officer of Novation Biosciences, a biotechnology software company (acquired by Agilent Technologies). He served on the board of directors of A Foundation Building Strength, a nonprofit organization with a mission to find treatments for nemaline myopathy, for more than a decade, in addition to serving on the board of directors of Neuromast, a specialty pharmaceutical company.

Mr. Quinn earned his master’s and bachelor’s degrees from Stanford University and an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller scholar.

Grant Yonehiro

Chief Business Officer

Grant Yonehiro, Chief Business Officer, joined Bolt Biotherapeutics in 2016. Mr. Yonehiro has been responsible for business and corporate development, st

Grant Yonehiro

Chief Business Officer

Grant Yonehiro, Chief Business Officer, joined Bolt Biotherapeutics in 2016. Mr. Yonehiro has been responsible for business and corporate development, strategy, commercialization, and general management within biotechnology companies for over 25 years with significant transactional and operational responsibilities. He served as president and chief executive officer of Perseid Therapeutics from inception through acquisition by Astellas Pharma and stayed on post-acquisition as president of an Astellas operating site. He served as chief business officer for Berkeley Lights and Maxygen Inc., and held various senior management positions at GenVec, Inc., including vice president of commercial operations, vice president of product management and vice president of drug development. Prior to GenVec, he served in business development at Cell Genesys, Inc. in investment banking at Piper Jaffray and in the Technology Transfer Office at Lawrence Berkeley National Laboratory.

Mr. Yonehiro graduated magna cum laude from the University of Minnesota with a Bachelor of Individualized Studies and received his MBA from the Haas School of Business at University of California, Berkeley.

Michael N. Alonso, Ph.D.

Vice President, Immunology & Pharmacology

Michael Alonso, Ph.D., Vice President, Immunology & Pharmacology, is scientific co-founder at Bolt Biotherapeutics and co-inventor of Bolt’s propri

Michael N. Alonso, Ph.D.

Vice President, Immunology & Pharmacology

Michael Alonso, Ph.D., Vice President, Immunology & Pharmacology, is scientific co-founder at Bolt Biotherapeutics and co-inventor of Bolt’s proprietary ISAC platform. Dr. Alonso is passionate about translating scientific discoveries into innovative therapies that ensure cancer patients become cancer survivors. Dr. Alonso brings deep expertise in myeloid biology and drug discovery, with more than a decade of research and translational experience in immunology, neuroscience, and transplant biology. Prior to joining Bolt, Dr. Alonso served as the lead scientist at a Bay Area biotechnology start-up company and held leadership roles at Stanford University.

Dr. Alonso is a well-published scientist who earned his Ph.D. from Stanford University School of Medicine and his Certificate in Entrepreneurship from the Stanford Graduate School of Business. Dr. Alonso graduated with distinction from the University of Illinois at Urbana-Champaign, where he obtained his Bachelor of Science degree in molecular and cellular biology.

Karen Bergman

Vice President, Communications and Investor Relations

Karen L. Bergman, Vice President, Communications and Investor Relations, brings more than two decades of life science corporate communications, investor

Karen Bergman

Vice President, Communications and Investor Relations

Karen L. Bergman, Vice President, Communications and Investor Relations, brings more than two decades of life science corporate communications, investor relations, and reputation-building experience to Bolt Biotherapeutics. Ms. Bergman has held leadership and advisory roles in investor relations and corporate, product, employee, and financial communications at a number of companies and consultancies.

Prior to joining Bolt, she served as vice president, investor relations and corporate communications at FibroGen, Inc., supporting multiple public equity financings, and the development of the company’s brand in the U.S. and China, among other responsibilities. Previously, Ms. Bergman was president and co-founder of BCC Partners, an investor relations and communications strategic advisory firm that guided leading biopharmaceutical companies from early to late-stage and commercial development. As vice president of corporate communications and Investor Relations at ALZA Corporation (now Johnson & Johnson), she supported the company’s transition to a successful, fully integrated commercial company. During her tenure, she oversaw investor relations programs supporting multiple strategic financings, broad analyst coverage and institutional ownership, and communications driving corporate reputation and brand recognition in specialty commercial areas, including oncology, urology, endocrinology, and neurology. Earlier, she led the life science practice at Burns McClellan Inc. in New York. Ms. Bergman has served on the board of directors and leadership committees for healthcare, education, biotech incubator, and investor relations organizations. She earned her bachelor’s degree at Yale University, where she graduated cum laude with distinction.

Wesley Burwell

Vice President, Head of Human Resources

Wesley Burwell, Vice President, Head of Human Resources, brings more than 20 years of experience in building and driving human resources and employee dev

Wesley Burwell

Vice President, Head of Human Resources

Wesley Burwell, Vice President, Head of Human Resources, brings more than 20 years of experience in building and driving human resources and employee development strategies for clinical-stage life science companies to Bolt Biotherapeutics. Prior to joining Bolt, Mr. Burwell was senior HR leader at Global Blood Therapeutics, where he supported the company’s exponential growth from early development through commercialization by leading talent acquisition and establishing internal programs to foster learning and development and employee engagement and retention. Over the course of his career, Mr. Burwell has held leadership roles in life science and technology companies, in addition to founding and building a successful recruiting and HR consulting practice. He has served on the board of directors for several non-profit organizations focused on healthcare and education. Mr. Burwell is passionate about building mission-driven organizations with strong cultures and diverse, inclusive workforces.

Mr. Burwell earned his MBA in international business from the University of San Francisco and B.A. in Human Resource Management from Golden Gate University.

Bruce Hug, M.D., Ph.D.

Senior Vice President, Clinical Development & Translational Medicine

Bruce Hug, M.D., Ph.D., Senior Vice President, Clinical Development & Translational Medicine, joined Bolt Biotherapeutics in 2021 with 20 years of ac

Bruce Hug, M.D., Ph.D.

Senior Vice President, Clinical Development & Translational Medicine

Bruce Hug, M.D., Ph.D., Senior Vice President, Clinical Development & Translational Medicine, joined Bolt Biotherapeutics in 2021 with 20 years of academic and pharmaceutical science experience. Prior to Bolt, Dr. Hug was a clinical development leader at GlaxoSmithKline, where he oversaw development of diverse immunotherapy platforms and targets. Dr. Hug has also held positions of increasing responsibility at CSL Behring and Wyeth, with development experience ranging from clinical pharmacology and translational medicine through Phase 3 clinical programs. Dr. Hug completed his residency and fellowship training and served as an assistant professor at the University of Pennsylvania.

Dr. Hug earned an M.D. and a Ph.D. from Washington University School of Medicine in St. Louis, where he studied gene regulation.

Nathan Ihle, Ph.D.

Senior Vice President, Pharmaceutical Operations

Nathan Ihle, Ph.D., Senior Vice President, Pharmaceutical Operations, joined Bolt Biotherapeutics in 2019, bringing nearly 30 years of experience in phar

Nathan Ihle, Ph.D.

Senior Vice President, Pharmaceutical Operations

Nathan Ihle, Ph.D., Senior Vice President, Pharmaceutical Operations, joined Bolt Biotherapeutics in 2019, bringing nearly 30 years of experience in pharmaceutical R&D, primarily in cancer drug development. Prior, he was the founder and principal at Ihle CMC Solutions. He also served as the vice president of manufacturing strategy at Immunomedics, Inc. (now Gilead Sciences), where he developed the supply strategy, supporting the global commercialization of the company’s first antibody-drug conjugate product, and was closely involved in the company’s regulatory submissions. Previously, Dr. Ihle worked for 16 years at Seattle Genetics, Inc. (now Seagen) as the vice president of CMC strategy and management, leading critical portions of the development of Adcetris (brentuximab vedotin) and other programs. At Seagen, Dr. Ihle was responsible for CMC aspects of development and regulatory strategies for all corporate programs, portfolio and project management, and alliance management.

Dr. Ihle completed his post-doctoral work as an American Cancer Society Postdoctoral fellow at the University of California, Berkeley after receiving his doctorate in organic chemistry from Stanford University.

Sarah Nemec

Vice President, Finance

Sarah Nemec, Vice President, Finance, joined Bolt Biotherapeutics in 2020, bringing more than 20 years as a senior finance leader in the life science ind

Sarah Nemec

Vice President, Finance

Sarah Nemec, Vice President, Finance, joined Bolt Biotherapeutics in 2020, bringing more than 20 years as a senior finance leader in the life science industry to the company. At Bolt, she is responsible for all aspects of the company’s financial planning, accounting, and reporting. Ms. Nemec played a key role in Bolt’s initial public offering and spearheaded all activities necessary to establish the company’s financial management infrastructure, key reporting systems and processes. Prior to joining Bolt, she served as the vice president, principal accounting executive for BioElectron Technology Corp., where she led accounting and cash management for the company through the sale and transition of its assets to PTC Therapeutics. Previously, Ms. Nemec served as the director, financial reporting for JDA Software (now Blue Yonder) and associate director, SEC reporting for Affymetrix (acquired by Thermo Fisher Scientific).

Ms. Nemec began her career as an auditor in the financial services and life science practice at Ernst & Young, LLP. Ms. Nemec is a certified public accountant and earned her bachelor’s and master’s degrees in accounting from Ohio University.

Brian Safina, Ph.D.

Senior Vice President, Discovery Research

Brian Safina, Ph.D., Senior Vice President, Discovery Research, has been a member of the Bolt Biotherapeutics leadership team since 2018 and brings more

Brian Safina, Ph.D.

Senior Vice President, Discovery Research

Brian Safina, Ph.D., Senior Vice President, Discovery Research, has been a member of the Bolt Biotherapeutics leadership team since 2018 and brings more than 18 years of drug discovery experience in the pharmaceutical and biotechnology industries. Prior to joining Bolt, Dr. Safina served in roles of increasing responsibility at Genentech, a member of the Roche Group, in discovery chemistry, including as project team leader for research and early-stage development programs, with responsibility for more than 30 team members. Over the course of his career, he has contributed to the discovery and development of clinical candidates targeting AKT (ipatasertib), Nav1.7 (GDC-0276, GDC-0310), and TRPA1. Dr. Safina's expertise spans multiple therapeutic areas and modalities including oncology, immunology, neuroscience, and cytotoxic ADCs. He has published more than 26 papers and is named on more than 50 granted patents and patent applications.

Dr. Safina holds a Ph.D. in organic chemistry from the University of California, San Diego, where he worked in the laboratories of K.C. Nicolaou, Ph.D., at The Scripps Research Institute.

John Tomaro

Vice President, Clinical Operations

John Tomaro, Vice President, Clinical Operations, joined Bolt Biotherapeutics in 2020 with 18 years of experience in clinical operations, including first

John Tomaro

Vice President, Clinical Operations

John Tomaro, Vice President, Clinical Operations, joined Bolt Biotherapeutics in 2020 with 18 years of experience in clinical operations, including first-in-human through Phase 3 clinical studies, primarily in oncology, immuno-oncology, and rare disease. Prior to joining Bolt, Mr. Tomaro led clinical operations at Sangamo Therapeutics, contributing to clinical development strategy across multiple programs. Before Sangamo, he held roles of increasing responsibility over a ten-year period at Celgene Corporation (now Bristol Myers Squibb), where he led multiple cross-functional teams in the execution of Phase 1-3 clinical trials. Mr. Tomaro previously worked in clinical operations at BioMarin Pharmaceutical and Quintiles Transnational (now IQVIA).

Mr. Tomaro received his master’s degree from the University of California at Santa Cruz and his bachelor’s degree from the University of North Carolina at Chapel Hill.

Lu Xu, Ph.D.

Vice President, Development Sciences

Lu Xu, Ph.D., Vice President, Development Sciences, joined Bolt Biotherapeutics in 2022, bringing 20 years of experience in the development of a range of

Lu Xu, Ph.D.

Vice President, Development Sciences

Lu Xu, Ph.D., Vice President, Development Sciences, joined Bolt Biotherapeutics in 2022, bringing 20 years of experience in the development of a range of antibody-based therapeutics, primarily in the field of oncology. Over the course of her career, Dr. Xu has led or supported new drug development programs from early-stage research through post-marketing commitment, including 12 INDs and two BLAs. Before joining Bolt, Dr. Xu was co-founder and head of drug development at PRAV Biosciences. Prior, she was head of preclinical development and clinical pharmacology at 23andMe Therapeutics, where she oversaw preclinical safety assessment, pharmacokinetics, biomarker discovery, and bioanalytics. Dr. Xu also served as the head of clinical pharmacology and preclinical pharmacokinetics at OncoMed Pharmaceuticals (now Mereo BioPharma Group), supporting the planning and execution of multiple oncology programs from pre-IND stage through Phase 2 clinical studies. Before joining OncoMed, she held drug development positions of increasing responsibility at Genentech, a member of the Roche Group, and Novartis.

Dr. Xu earned a Ph.D. in biomedical engineering and an M.S. in regulatory science from the University of Southern California, and an M.S. in biochemistry from University of California, Riverside.

Ming Yin, Ph.D.

Vice President, Head of Biometrics

Ming Yin, Ph.D., Vice President, Head of Biometrics, joined Bolt Biotherapeutics in 2022. Dr. Yin brings more than 20 years of industry experience across

Ming Yin, Ph.D.

Vice President, Head of Biometrics

Ming Yin, Ph.D., Vice President, Head of Biometrics, joined Bolt Biotherapeutics in 2022. Dr. Yin brings more than 20 years of industry experience across all phases of clinical development in a wide range of therapeutic areas. Dr. Yin most recently served as executive director, head of biostatistics at Loxo Oncology at Lilly, where he oversaw statistical activities on multiple drug development programs, including BTK inhibitor, BCL2 inhibitor and next-generation RET programs, and led planning, execution, and quality delivery of statistical analyses for two NDA submissions. He also made significant contributions to the study design and implementation of five pirtobrutinib Phase 3 clinical studies. Before joining Loxo, Dr. Yin was the director of biostatistics at Acerta Pharma, a member of the AstraZeneca Group, where he led the statistical activities for hematology programs and clinical pharmacology studies and made significant contributions to the approval of Calquence (acalabrutinib) for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Prior to Acerta, Dr. Yin worked at Genentech, a member of the Roche Group, for 10 years, where he was a lead biostatistician for pivotal clinical trials across three disease areas (immunology, neurology, and oncology) and a key contributor to the approval of Rituxan (rituximab) for rheumatoid arthritis, Ocrevus (ocrelizumab) for multiple sclerosis, Zelboraf (vemurafenib), and Cotellic (cobimetinib) for melanoma.

Dr. Yin holds a Ph.D. in statistics from the University of Florida and master’s degree in statistics from Peking University.

Board of Directors

Edgar G. Engleman, M.D.

Founder and Director

Dr. Ed Engleman is professor of pathology and medicine at Stanford University Sc

Edgar G. Engleman, M.D.

Founder and Director

Dr. Ed Engleman is professor of pathology and medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. He is also co-director of the Immunology and Immunotherapy Program of the Stanford Cancer Institute. Dr. Engleman has authored more than 300 publications in medical and scientific journals and has trained more than 100 graduate students and postdoctoral scholars, many of whom have gone on to successful careers in industry and academia. Dr. Engleman is a co-founder and managing partner of Vivo Capital, a leading healthcare focused investment firm with offices in the U.S. and Asia. He has also co-founded a number of biopharmaceutical companies including Genelabs, Dendreon, Medeor and Tranquis. He is the lead inventor of the technology underlying Sipuleucel-T (Provenge), which was shown to extend life for patients with metastatic prostate cancer and was the first active immunotherapeutic agent to be approved by the FDA. Recently, Dr. Engleman’s laboratory discovered a promising new immunotherapy that activates dendritic cells in tumors in situ without requiring their removal and activation in vitro. This treatment was shown to eradicate a wide range of tumors in mouse models and provided the basis for the creation of Bolt Biotherapeutics. Dr. Engleman currently serves on the boards of several private biotechnology companies including Bolt. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.

Jim Healy, M.D., Ph.D.

Lead Independent Director

Jim Healy, M.D. Ph.D., is a General Partner of Sofinnova Investments with over 2

Jim Healy, M.D., Ph.D.

Lead Independent Director

Jim Healy, M.D. Ph.D., is a General Partner of Sofinnova Investments with over 20 years of experience funding innovative therapies. He is currently on the board of directors for Ascendis (ASND), Bolt (BOLT), Coherus (CHRS), Karuna (KRTX), Natera (NTRA), Nucana (NCNA), Y-mAbs (YMAB), and a board observer at Visen. Prior to Sofinnova, Dr. Healy held positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals, and ISTA Pharmaceuticals, Inc. Additionally, Dr. Healy has extensive board experience, serving on both private and public company boards, including Amarin Corporation, Auris Medical Holding AG, Edge Therapeutics, and Hyperion Therapeutics, as Chairman of the Board. In 2011, Dr. Healy won the IBF Risk Innovator Award and was named as one of the industry’s top leading Life Science investors in 2013 by Forbes Magazine. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.

Kathleen LaPorte

Director

Kathy LaPorte has more than 30 years of experience building and operating private and public biotech companies

Kathleen LaPorte

Director

Kathy LaPorte has more than 30 years of experience building and operating private and public biotech companies. She currently serves as a director of Elysium Therapeutics, Precipio Diagnostics and D2G Oncology. Kathy was chief executive officer of Nodality Inc. as well as a founding partner of New Leaf Ventures, which was a spinout from the Sprout Group. Prior to that, Kathy served as a general partner of The Sprout Group for over 12 years.   She is passionate about helping founders, CEOs and organizations grow successfully and playing a meaningful role on outstanding boards. Kathy’s board experience is extensive and includes both private and public companies, as well as public-sector boards such as the California Institute of Regenerative Medicine (CIRM).  She has served on more than a dozen public company boards, including companies such as Affymax, ISTA Pharmaceuticals, and Onyx Pharmaceuticals.  Kathy has served on 12 audit committees, and chaired several. She is a Qualified Financial Expert. Kathy has a B.S. degree in Biology from Yale University and an M.B.A. from the Stanford University Graduate School of Business.

Frank D. Lee

Director

With over 25 years’ global experience in product development and commercial leadership across a wide range o

Frank D. Lee

Director

With over 25 years’ global experience in product development and commercial leadership across a wide range of therapeutic areas within the biotech and pharmaceutical industry, Frank joined as chief executive officer of Forma Therapeutics in March 2019. Most recently serving as senior vice president, global product strategy and therapeutic area head for the immunology, ophthalmology and infectious diseases at Genentech, a member of the Roche Group, he was responsible for driving development and commercial strategy for a broad portfolio of molecules in development and for global in-line product sales of more than $11 billion. Frank’s 13-year career path at Genentech included leadership positions of increasing scope and responsibility for delivering transformative medicines to patients. Previously, as vice president of the HER2/Breast Cancer Franchise, Frank was responsible for the U.S. P&L for Herceptin®, Perjeta® and Kadcyla®, driving revenues over $4 billion and launching the first HER2 neoadjuvant indication shaping a new market and treatment paradigm for early HER2 breast cancer patients. As vice president of oral oncolytics, Frank held P&L responsibility for Tarceva®, Zelboraf®, Erivedge® and Xeloda®, advancing personalized medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma and establishing a new treatment option for patients with advanced basal cell carcinoma. Prior to joining Genentech, Frank spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development. Frank received a bachelor’s degree in chemical engineering from Vanderbilt University and an MBA in marketing and finance from the Wharton Graduate School of Business. He previously served on the board of directors of the Genentech Foundation.

Richard A. Miller, M.D.

Director

Dr. Richard Miller currently serves as co-founder, president and chief executive

Richard A. Miller, M.D.

Director

Dr. Richard Miller currently serves as co-founder, president and chief executive officer of Corvus Pharmaceuticals, a public biotechnology company. He co-founded and was chief executive officer of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, vice president and director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude and completed residency and fellowship programs in internal medicine and medical oncology at Stanford University Medical Center. He is a board-certified oncologist and is currently adjunct clinical professor of medicine (oncology) at Stanford University Medical Center.

Brian O'Callaghan

Director

Brian O’Callaghan is a Life Science Executive with extensive experience within the biotech, big pharma and C

Brian O'Callaghan

Director

Brian O’Callaghan is a Life Science Executive with extensive experience within the biotech, big pharma and CRO sectors. He also has extensive global experience, having lived and worked in 5 different countries, as well as both sides of the US. He joined ObsEva in November 2020, as Chief Executive Officer to lead the Company through its future development, regulatory filings and product launches.

Prior to joining ObsEva, Brian has held CEO positions at Petra Pharma, Acucela, Sangart and BioPartners, as well as having held senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals.

Brian has experience running both public and private companies, M&A’s, IPO’s, fundraising, divestments, spin-outs and strategic alliances. His operational experience is also wide ranging, having managed multiple businesses and programs, across many therapeutic areas, from concept through to commercialization. He also has extensive Board experience, having served on numerous biotech and 501c3 Boards.

Nicole Onetto, M.D.

Director

Nicole Onetto, M.D., is an independent consultant in oncology, drug development, and translational research. S

Nicole Onetto, M.D.

Director

Nicole Onetto, M.D., is an independent consultant in oncology, drug development, and translational research. She is currently on the board of directors for Viracta Therapeutics, Basilea Pharmaceutica and Bolt Biotherapeutics, and previously held director roles at NBE Therapeutics, Sierra Oncology, and ImmunoGen. She was Deputy Director and Chief Scientific Officer at the Ontario Institute for Cancer Research from 2009 to 2016. Prior to that, Dr. Onetto held the role of Chief Medical Officer at ZymoGenetics (Bristol Myers Squibb) and at OSI Pharmaceuticals (Astellas). Her career also includes senior management positions at Bristol Myers Squibb, Nexstar Pharmaceuticals (Gilead) and Immunex Corporation (Amgen). Dr. Onetto earned her bachelor’s degree from the University of Paris, a master’s degree in Pharmacology from the University of Montréal, and her medical degree and a Hematology-Oncology Certificate from the University of Paris.

Randall Schatzman, Ph.D.

CEO and Board Member

Dr. Randall Schatzman, Chief Executive Officer and board member, joined Bolt Bio

Randall Schatzman, Ph.D.

CEO and Board Member

Dr. Randall Schatzman, Chief Executive Officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.

Mahendra G. Shah, Ph.D.

Director

Dr. Mahendra G. Shah is a pharmaceutical entrepreneur and executive who has been

Mahendra G. Shah, Ph.D.

Director

Dr. Mahendra G. Shah is a pharmaceutical entrepreneur and executive who has been at healthcare investment firm, Vivo Capital, since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves on the boards of Homology Medicines Inc. (NASDAQ: FIXX) and Soleno Therapeutics Inc (NASDAQ: SLNO), and is a member of the board of trustees of St. John’s University. Dr. Shah is also a board member and charter member of EPPIC and a charter member of TIE.

From 2005 to 2009, he was the founder, chairman and chief executive officer of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company, which was sold to Pfizer for a total of $700 million in upfront and milestone payments. From 1993 to 2003 he was the chairman and chief executive officer of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he raised over $200 million and built a highly profitable company before it was sold to Shionogi Pharmaceuticals for $1.4 billion. Prior to that, he held positions with E. J. Financial Enterprises, which manages a fund that invests in healthcare companies and with Fujisawa USA (Astellas), and before that, he worked in various scientific and management positions with Schering-Plough and Bristol Myers-Squibb. He previously served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics (INGN), Inpharmakon, Protomed, Structural Bioinformatics, and Zarix. Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and his Bachelors and Masters Degrees in Pharmacy from L.M. College of Pharmacy in Gujarat, India.

Scientific Advisory Board

Lawrence Fong, M.D.

Cancer Immunotherapy Program Leader

Lawrence Fong, M.D., is an Efim Guzik distinguished professor in the Division of Hematology/Oncology at the Un

Lawrence Fong, M.D.

Cancer Immunotherapy Program Leader

Lawrence Fong, M.D., is an Efim Guzik distinguished professor in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF). Dr. Fong is focused on developing immunotherapies for different cancers including prostate, kidney, bladder, melanoma, and GI cancers. As a physician-scientist, Dr. Fong also leads a translational immunotherapy laboratory. He has been involved in both pre-clinical and clinical studies for many cutting-edge immunotherapies. Dr. Fong obtained his M.D. at Stanford University, completed internal medicine training at the University of Washington, and an oncology fellowship at Stanford University with Drs. Ed Engleman and Mark Davis focused on tumor immunology. He served on the program committees and editorial boards for ASCO and AACR. He is co-director of the Parker Institute for Cancer Immunotherapy at UCSF and is the site primary investigator for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN).

Priti Hegde, Ph.D.

Chief Scientific Officer

As chief scientific officer at Foundation Medicine, Priti Hegde, Ph.D., oversees clinical product development,

Priti Hegde, Ph.D.

Chief Scientific Officer

As chief scientific officer at Foundation Medicine, Priti Hegde, Ph.D., oversees clinical product development, cancer genomics and early-stage research, as well as regulatory strategies for the company’s comprehensive genomic profiling portfolio. Prior to joining Foundation Medicine, Dr. Hegde spent 12 years at Genentech, a member of Roche Group, most recently serving as senior director and principal scientist in oncology biomarker development, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy. Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union as well as its forthcoming diagnostic filings. Prior to Genentech, she worked at GlaxoSmithKline. Dr. Hegde completed her post-doctoral fellow at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy from Mumbai University, India.

Roy S. Herbst, M.D., Ph.D.

Chief of Medical Oncology, Director for Translational Research

Roy S. Herbst, M.D., Ph.D., is ensign professor of medicine, professor of pharmacology, chief of medical oncol

Roy S. Herbst, M.D., Ph.D.

Chief of Medical Oncology, Director for Translational Research

Roy S. Herbst, M.D., Ph.D., is ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research at Yale Cancer Center (YCC) and Yale School of Medicine. Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy, serving as principal investigator for numerous clinical trials for advanced stage lung cancers. This work led to the approval of several therapies (such as Gefitinib, Cetuximab, Bevacizumab, Axitinib, Atezolizumab, and Pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. He works closely with public-private partnerships to develop large clinical studies, such as Lung-MAP. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology (ASCO). Dr. Herbst’s work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

Nils Lonberg, Ph.D.

Executive in Residence

Nils Lonberg is currently an Executive in Residence at Canaan Partners. Dr. Lonberg led drug discovery and pla

Nils Lonberg, Ph.D.

Executive in Residence

Nils Lonberg is currently an Executive in Residence at Canaan Partners. Dr. Lonberg led drug discovery and platform development teams in the biotech and pharma industry for the last 30 years, most recently as Senior Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb. Prior to that he was Scientific Director at Genpharm International and Medarex, where his research groups developed genetically engineered strains of mice with human immunoglobulin genes that have been used to discover 10 FDA-approved antibody therapeutics, including ipilimumab and nivolumab, two drugs discovered by Dr. Lonberg’s team that target immune-attenuating pathways to activate patient immune responses to multiple cancers (so-called "checkpoint blockade" therapies). Dr. Lonberg received his PhD in Biochemistry and Molecular Biology from Harvard University (Cambridge, MA) in 1985, and was elected to the National Academy of Engineering in 2015.

Bruce D. Roth, Ph.D.

Principal

Bruce D. Roth, Ph.D. is best known as the inventor of Lipitor®, for which he has received numerous awards, in

Bruce D. Roth, Ph.D.

Principal

Bruce D. Roth, Ph.D. is best known as the inventor of Lipitor®, for which he has received numerous awards, including the 2013 Perkin Medal, the highest award given to industrial chemists in the United States. Dr. Roth is now active as a biopharmaceutical research consultant. Prior to founding his consulting practice, between the years of 2007 and 2017, he held positions of increasing responsibility at Genentech, the last one being senior vice president of gRED (Genentech Research and Early Development) small molecule drug discovery and co-leader of gRED research. Before that, he served as vice president of chemistry at Pfizer Global Research and Development, Ann Arbor Laboratories, and prior to that, was an adjunct associate professor in the Department of Medicinal Chemistry in the School of Pharmacy of the University of Michigan.